Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2021 | Phase II and III studies of CNM-Au8 in ALS

Robert Glanzman, MD, FAAN, Clene Inc., Salt Lake City, UT, shares the details of studies assessing CNM-Au8 as a novel therapeutic agent for use in amyotrophic lateral sclerosis (ALS). The Phase II RESCUE-ALS trial (NCT04098406) is a randomized placebo-controlled study of the efficacy and safety of CNM-Au8 as a novel disease-modifying agent. Mean change in the average difference between placebo and active drug MUNIXscore from baseline to 36 weeks was assessed as the primary endpoint. The study is complete, and analysis is ongoing. CNM-Au8 is also being assessed in a Phase III multicenter, multi-regimen platform trial (HEALEY ALS; NCT04297683). This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.


Dr Glanzman is an employee of Clene Nanomedicine Inc.